Revance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights

Core Viewpoint - Revance Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between February 29, 2024, and December 6, 2024 [1][2] Group 1: Allegations and Impact - The lawsuit claims that Revance was in material breach of its Distribution Agreement with Teoxane, which granted exclusive rights to import, market, promote, sell, and distribute Teoxane's dermal fillers [2] - This breach allegedly increased the risk of litigation and resulted in potential monetary and reputational harm to the company [2] - The situation heightened the risk that a tender offer would be delayed or amended, leading to materially false and misleading public statements from the company [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until March 4, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, indicating no financial obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders over the past 20 years and is recognized as one of the top securities litigation firms in the United States [4]